Table 4.

Top ten scored repurposed drug candidates based on COVID-19 specific hub proteins.

Drug name	Mechanism of Action	Approval Status	Associated Conditions	Reference
SYK-inhibitor	spleen tyrosine kinase inhibitor	investigational	chronic immune thrombocytopenia	Bussel et al. (2018);
Radicicol	HSP90 tyrosine kinase inhibitor with antifungal macrolactone antibiotic activity	approved	fungal infections, prostate cancer	Wu et al. (2013); Harashima et al., 2005
Dabrafenib	BRAF inhibitor with antineoplastic activity	approved	metastatic melanoma, thyroid cancer	Hauschilde et al. (2012); Subbiah et al. (2018)
AT-7519	CDK inhibitor leading to tumor regression	approved	cervical cancer, colon cancer	Xi et al. (2019)
Dasatinib	SRC family tyrosine kinase receptor inhibitor	approved	chronic myeloid leukemia, lung cancer	Kantarjianet al., 2010; Li et al. (2010)
Lovastatin	Inhibitor of HMG-CoA reductase (3-hydroxy-3-methylglutaryl-coenzyme A) with antilipemic activity	approved	cardiovascular diseases	Tobert (2003)
Thiostrepton	A cyclic oligopeptide and protein synthesis inhibitor, FOXM1 inhibitor with antibiotic activity	approved	colon cancer, lung cancer	Ju et al. (2015); Huang et al. (2019)
Linifanib	RTK inhibitor with antineoplastic activity	approved	gastric cancer, hepatocellular carcinoma	Chen et al. (2016); Cainap et al. (2015)
JNK–IN–5A	Selective inhibitor of JNK2 and JNK3	Investigational	not available	Angell et al. (2007)
Withaferin-A	Steroidal lactone with anti-inflammatory, antiangiogenic, antifungal, and anticancer activities	Investigational	fungal infections, ovarian cancer, breast cancer	Kakar et al. (2017); Stan et al. (2008)